Pharmaceutical News

RSS

Rituxan drug effective for treating ANCA-associated vasculitis

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.

19 Oct 2009

Recently approved Gleevec drug for cancer treatment

Investigators have identified a drug that is currently approved to treat certain types of cancer, Gleevec, that could provide the first treatment for scleroderma, a chronic connective tissue disease for which a treatment has remained elusive. The news will be presented at the annual meeting of the American College of Rheumatology on October 18 in Philadelphia.

19 Oct 2009

Findings may yield new treatments for COPD

A genetic mutation found in four children born with multiple abnormalities may provide insight into potential treatments for newborn lung distress and chronic obstructive pulmonary disease (COPD).

19 Oct 2009

CK Life Sciences acquires additional voting shares of WEX Pharmaceuticals

CK Life Sciences Int'l., (Holdings) Inc. ("CKLS") of Hong Kong (Hong Kong Stock Exchange Limited Stock Code 0775) and WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that CKLS has acquired an additional 116,852,062 restricted voting shares of WEX to bring its holding to 133,179,334 restricted voting shares, or 75.25% of the total outstanding restricted voting shares.

19 Oct 2009

GlaxoSmithKline receives FDA approval for cervical cancer vaccine

GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved CERVARIX® [Human papillomavirus bivalent (types 16 and 18) vaccine, recombinant] for the prevention of cervical pre-cancers and cervical cancer associated with oncogenic human papillomavirus (HPV) types 16 and 18 for use in girls and young women (aged 10-25).

19 Oct 2009

Multi-million dollar cooperative agreement for SMA drug development program

Paratek Pharmaceuticals (Boston, MA) and Families of Spinal Muscular Atrophy (Elk Grove Village, IL) announced today that a jointly funded drug development program for Spinal Muscular Atrophy (SMA) has been awarded a multi-million dollar cooperative agreement from the National Institute of Neurological Disorders and Stroke (NINDS).

19 Oct 2009

FDA approves 100th antiretroviral for PEPFAR

HHS recently announced the FDA's 100th approval of an antiretroviral drug for PEPFAR, PharmTech.com reports. Seventy-one of the more than 100 drugs reviewed by FDA for PEPFAR were generic products.

19 Oct 2009

Access Pharmaceuticals' update on its European commercial launch of Mugard

ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.

15 Oct 2009

FDA launches web page with information on how to dispose of certain drugs

The U.S. Food and Drug Administration today launched a Web page for consumers with information on how to dispose of certain drugs, including several high-potency opioids and other selected controlled substances.

15 Oct 2009

Mylan Pharmaceuticals receives approval for Topiramate Capsules

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Topiramate Capsules (Sprinkle), 15 mg and 25 mg.

15 Oct 2009

MDS secures international cooperation to help Canadian teenager with malignant blood disorder

The Myelodysplastic Syndromes (MDS) Foundation says a wide range of international cooperation has been secured to help 18-year-old Wes Laporte of Ontario get treatment for a life-threatening condition in the US.

15 Oct 2009

AcelRx Pharmaceuticals’ programs to feature at upcoming annual meeting

AcelRx Pharmaceuticals, Inc. announced today that results of its Phase 1 studies evaluating the pharmacokinetics of its oral transmucosal NanoTab(TM) formulation of sufentanil will be featured in two oral presentations at the upcoming American Society of Anesthesiologists Annual Meeting in New Orleans.

15 Oct 2009

European authorities approve Medivir’s marketing authorisation application in 14 European countries

The European regulatory authorities have now approved Medivir’s marketing authorisation application in 14 European countries. The trademark for the product in Europe will be XerclearTM.

15 Oct 2009

Northern Light partners with EBSCO Publishing to provide bio-pharma and health sciences news

Northern Light (www.northernlight.com) today announced a partnership with EBSCO Publishing (EBSCO) (www.ebscohost.com) that will let mutual customers directly search and access more than 4,000 bio-pharmaceutical, health sciences and general business magazines, journals and other news sources through Northern Light SinglePoint(TM) strategic research portals.

15 Oct 2009

Pharma IQ reports on the 7th Annual Cold Chain Distribution for Pharmaceuticals conference

Pharma IQ, a division of IQPC, held the 7th Annual Cold Chain Distribution for Pharmaceuticals, September 21-24, 2009 at the Pennsylvania Convention Center in Philadelphia, PA. This industry-leading global forum gathered more than 350 pharmaceutical, regulatory and logistic experts to address the greatest challenges supply chain professionals face today.

From IQPC Ltd 15 Oct 2009

BNA Books publishes the 2009 Cumulative Supplement to Pharmaceutical Patent Law

The 2009 Cumulative Supplement to Pharmaceutical Patent Law delivers the latest legal developments in pharmaceutical patent law.

15 Oct 2009

Negative symptoms represent an attractive target for drug development

A half-day workshop on issues in the design of clinical trials to evaluate treatments for negative symptoms of schizophrenia, chaired by Stephen Marder, MD, UCLA Department of Psychiatry and David Daniel, M.D., United BioSource Corporation was held 5 October 2009, as part of the International Society for CNS Clinical Trials and Methodology (ISCTM) Autumn Conference in San Diego, CA.

15 Oct 2009

Patients on statin drugs may have lower AAA surgery costs

Patients taking cholesterol-lowering statin drugs may have better results and lower procedure costs when having a common operation for repairing a bulging aorta, according to a new study presented at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

PIKAMAB obtains U.S. patent rights to develop theragnostic product

PIKAMAB, a stratified medicine biopharmaceutical company, announced today that it has secured exclusive rights to two issued U.S. patents from Hospital for Special Surgery, New York. PIKAMAB is developing Lupus TherasightTM, a novel theragnostic product that will eventually help guide the drug development process and patient treatment protocols in the areas of lupus and lupus nephritis.

15 Oct 2009

Survey reports patients' concern about the safety and access to flu vaccines

Although some parents may be lukewarm to the H1N1 vaccination, Lakeside Community Healthcare www.LakesideCommunityHealthcare.com, one of Southern California's largest integrated, comprehensive healthcare organizations, reports broader patient concern about both the safety of and access to the vaccine.

15 Oct 2009